Hyperimmune Plasma in Patients with COVID-19

Delvalle has supplied stainless steel junction boxes for pharmaceutical industry in the development of specific immunoglobulins used in the treatment and prevention of infections and that have been applied to healthcare emergencies like the Ebola outbreak. The production of anti-SARS-CoV-2 hyperimmune immunoglobulins are being produced in its Clayton (North Carolina, U.S.) facility, which has been specifically designed to process specialty immunoglobulins.

The production of this potential anti-COVID-19 passive immune therapy as part of a collaboration agreement with U.S. government entities, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the Biomedical Advanced Research Development Authority (BARDA), among other healthcare agencies.

RESEARCH IN SPAIN

At the same time, it is moving forward with its clinical trial in Spain to assess the effectiveness of high-dose intravenous immunoglobulin to stabilize or improve the condition of COVID-19 patients.

In this regard, the trial aims to assess the action of neutralizing antibodies (proteins that bind viruses and prevent them from infecting human cells), as well as determine the immunomodulatory potential (immune modulation response) of immunoglobulins as therapy to block the cytokine storm in patients with severe cases of COVID-19.

SOLUTION BY DELVALLE

After identifying the requirements of the pharmaceutical industry, Delvalle developed with the client the UL Nema Type 4X stainless steel enclosures, Luxor Series and Tribeca Series.

With this solution, we can ensure the right conditions to this sector that requires special requirement according to EU and international regulations.